Abecma
The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.
Bristol Myers Squibb to Acquire 2seventy Bio for $286M
2seventy sold most of its pipeline candidates except for CAR T-cell therapy Abecma to Regeneron last year.
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies.
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
Jul 26, 2024
Apr 25, 2024